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Dysregulation and Associated With Enhanced Activation of Forkhead Box O1 
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Abstract 
Aims/hypothesis 
The role of TNF-α in impaired wound healing in diabetes was examined by focusing on fibroblasts. 
Methods 
Small excisional wounds were created in the db/db mice model of type 2 diabetes and normoglycaemic 
littermates, and in a streptozotocin-induced type 1 diabetes mouse model and control mice. Fibroblast 
apoptosis was measured by the TUNEL assay, proliferation by detection of proliferating cell nuclear 
antigen, and forkhead box O1 (FOXO1) activity by DNA binding and nuclear translocation. TNF-α was 
specifically inhibited by pegsunercept. 
Results 
Diabetic wounds had increased TNF-α, fibroblast apoptosis, caspase-3/7 activity and activation of the 
pro-apoptotic transcription factor FOXO1, and decreased proliferating cell nuclear antigen positive 
fibroblasts (p < 0.05). TNF-α inhibition improved healing in the diabetic mice and increased fibroblast 
density. This may be explained by a decrease in fibroblast apoptosis and increased proliferation when 
TNF-α was blocked (p < 0.05). Although decreased fibroblast proliferation and enhanced FOXO1 activity 
were investigated in type 2 diabetes, they may also be implicated in type 1 diabetes. In vitro, TNF-α 
enhanced mRNA levels of gene sets related to apoptosis and Akt and p53 but not mitochondrial or cell-
cycle pathways. FOXO1 small interfering RNA reduced gene sets that regulate apoptosis, Akt, 
mitochondrial and cell-cycle pathways. TNF-α also increased genes involved in inflammation, cytokine, 
Toll-like receptor and nuclear factor-kB pathways, which were significantly reduced by FOXO1 knockdown. 
Conclusions/interpretation 
These studies indicate that TNF-α dysregulation in diabetic wounds impairs healing, which may involve 
enhanced fibroblast apoptosis and decreased proliferation. In vitro, TNF-α induced gene sets through 
FOXO1 that regulate a number of pathways that could influence inflammation and apoptosis. 
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Abstract
Aims/hypothesis—The role of TNF-α in impaired wound healing in diabetes was examined by
focusing on fibroblasts.
Methods—Small excisional wounds were created in the db/db mice model of type 2 diabetes and
normoglycaemic littermates, and in a streptozotocin-induced type 1 diabetes mouse model and
control mice. Fibroblast apoptosis was measured by the TUNEL assay, proliferation by detection
of proliferating cell nuclear antigen, and forkhead box O1 (FOXO1) activity by DNA binding and
nuclear translocation. TNF-α was specifically inhibited by pegsunercept.
Results—Diabetic wounds had increased TNF-α, fibroblast apoptosis, caspase-3/7 activity and
activation of the pro-apoptotic transcription factor FOXO1, and decreased proliferating cell
nuclear antigen positive fibroblasts (p<0.05). TNF-α inhibition improved healing in the diabetic
mice and increased fibroblast density. This may be explained by a decrease in fibroblast apoptosis
and increased proliferation when TNF-α was blocked (p <0.05). Although decreased fibroblast
proliferation and enhanced FOXO1 activity were investigated in type 2 diabetes, they may also be
implicated in type 1 diabetes. In vitro, TNF-α enhanced mRNA levels of gene sets related to
apoptosis and Akt and p53 but not mitochondrial or cell-cycle pathways. FOXO1 small interfering
RNA reduced gene sets that regulate apoptosis, Akt, mitochondrial and cell-cycle pathways. TNF-
α also increased genes involved in inflammation, cytokine, Toll-like receptor and nuclear factor-
kB pathways, which were significantly reduced by FOXO1 knockdown.
Conclusions/interpretation—These studies indicate that TNF-α dysregulation in diabetic
wounds impairs healing, which may involve enhanced fibroblast apoptosis and decreased
proliferation. In vitro, TNF-α induced gene sets through FOXO1 that regulate a number of
pathways that could influence inflammation and apoptosis.
Keywords
Diabetes; Fibroblast; FOXO; Nuclear translocation; PCNA; Proliferation; TNF-α
Introduction
A serious complication of diabetes is impaired healing, which can lead to diminished
physical activity and in some cases chronic wounds and limb amputation [1–4]. Multiple
factors are likely to contribute to deficient healing in patients with diabetes. They include an
altered host response, diminished anti-bacterial defences, prolonged inflammation, altered
protease activity, a tendency for vascular abnormalities, the generation of an inadequate
number of cells to accomplish rapid and robust healing, decreased growth factor production,
a failure to form a sufficient amount of extracellular matrix, and alterations in apoptosis that
may interfere with healing by decreasing the number of cells that participate in new tissue
formation [2, 5–13].
Wound healing is a complex process that involves inflammation, formation of granulation
tissue, production of new structures and tissue remodelling [14, 15]. These processes are
regulated by cytokines and growth factors and modulated by systemic conditions such as
diabetes [4, 11]. A critical component of a vigorous healing response is the generation of a
sufficient number of cells to participate in repair. Processes that interfere with the ability to
produce enough cells, such as inappropriately high levels of fibroblast apoptosis, may limit
healing [16, 17]. On the other hand, apoptosis of cells at later stages of healing is important
in removing cells that are no longer needed [18–20].
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A potential mechanism through which diabetes may increase apoptosis is the excessive
production of the TNF-α pleiotropic cytokine that plays an important role in inflammation
and immunity [21]. Overproduction of TNF-α is thought to contribute to a number of
disease processes associated with persistent inflammation and tissue destruction [22–24].
TNF-α levels are elevated in non-healing ulcers [4] and associated with impaired healing in
type 2 diabetes mouse models [25]. Chronic elevation of TNF-α has been shown to impair
cutaneous wound healing and to cause a decrease in collagen production, while exogenous
TNF-α results in a decrease in wound strength [26, 27]. Moreover, TNF-α is associated with
the aetiological processes in both type 1 and type 2 diabetes [28, 29], as well as diabetic
complications. For example, high levels of TNF-α are involved in diabetic retinopathy and
nephropathy associated with both forms of diabetes [30, 31]. To investigate the contribution
of TNF-α to diminished wound healing in diabetes, we created small wounds in db/db and
matched normoglycaemic littermates, and in a streptozotocin-induced mouse model of type
1 diabetes and control mice.
The results indicate that diabetes enhanced TNF-α levels, decreased fibroblast density and
proliferation and increased fibroblast apoptosis and activation of the pro-apoptotic
transcription factor, forkhead box O1 (FOXO1). When TNF-α is blocked there is improved
healing, increased fibroblast proliferation and reduced apoptosis and greater fibroblast
density in the diabetic group. Fibroblast proliferation and FOXO1 activity were investigated
only in a type 2 diabetes model. However, the same pathways may be involved in type 1
diabetes. In vitro studies were carried out to examine the effect of TNF-α on fibroblasts and
the role of the transcription factor FOXO1 in microarray experiments in conjunction with
RNA interference (RNAi). Gene set enrichment analysis (GSEA) of mRNA profiling results
indicates that FOXO1 plays an important role in both pro-apoptotic and pro-inflammatory
gene expression and may thereby contribute to impaired healing in diabetes. The latter
represents a previously unrecognised role of FOXO1.
Methods
Preparation of the animals
Genetically diabetic C57BL/KsJ-Lepr−/− (db/db) mice and their non-diabetic littermates,
C57BL/KsJ-Lepr−/+ (db/db+), were purchased from the Jackson Laboratory (Bar Harbor,
ME, USA). They exhibit many aspects of diabetes impaired wound healing seen in humans
[6, 8, 10, 25, 32]. Eight-week-old male CD-1 mice (Charles River Laboratories,
Wilmington, MA, USA) were rendered diabetic by multiple low dose i.p. injection of
streptozotocin (40 mg/kg; Sigma, St Louis, MO, USA) in 10 mmol citrate buffer daily for 5
days, as we have previously described [33]. Control mice were treated identically with
vehicle alone, 10 mmol citrate buffer. Mice were considered to be hyperglycaemic when
serum glucose levels were >13.875 mmol/l. Experiments were started when mice had been
hyperglycaemic for at least 3 weeks, with typically n=6 mice per group. Two excisional
wounds of 1.5 mm were made in the scalp with a 1.5 mm disposable biopsy punch, as we
have previously described [34, 35]. Small wounds heal by connective tissue fill and
epithelial bridging rather than by contraction, do not require an occlusal dressing and rarely
become infected [35, 36]. Pegsunercept, generously provided by Amgen (Thousand Oaks,
CA, USA), was administered by i.p. injection (5 mg/kg). Pegsunercept is a recombinant
soluble TNF receptor type 1 (TNF-R1) linked to polyethylene glycol, which has been shown
to be specific, highly efficacious and minimally toxic [37]. It has been reported that a
pegsunercept-related molecule, etanercept, binds to soluble TNF-α but has reduced avidity
for membrane-integrated forms of TNF-α [38]. However, studies have also reported that
TNF-R1-based inhibitors also block membrane-bound TNF-α [39, 40]. To avoid interfering
with the early inflammatory events, pegsunercept was administered starting 2 days after
wounding and on days 5 and 8 based on its half-life of approximate 4 days [37]. Mice were
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killed at the indicated time points by CO2 overdose and decapitation. All animal procedures
were approved by the Institutional Animal Care and Use Committee, Boston University
Medical Centre.
Histological analysis
The scalp and attached calvarial bone were fixed in 4% (wt/vol.) paraformaldehyde and
decalcified in Immunocal (Decal Chemical Corporation, Congreve, NY, USA). Five
micrometre sagittal paraffin sections were prepared. The epithelial and connective tissue
gaps and the per cent connective tissue fill at the wound site were measured with computer-
assisted image analysis in haematoxylin and eosin-stained sections taken at the centre of
each lesion. Polymorphonuclear leucocytes (PMNs) were identified by their characteristic
appearance in haematoxylin and eosin-stained sections at ×1,000 magnification. Fibroblasts
were identified by immunohistochemistry using an antibody against heat-shock protein 47
(HSP47; Stressgen, Ann Arbor, MI, USA), a specific fibroblast marker [41]. There was no
immunostaining with matched control IgG (data not shown). In some experiments,
immunohistochemistry was combined with a TUNEL assay in situ by means of an ApopTag
Peroxidase In Situ Kit (Chemicon, Temecula, CA, USA). HSP47 was localised by detection
with a biotin-labelled secondary antibody and avidin–biotin–alkaline phosphatase complex
with Vector Red substrate (Vector Laboratories, Burlingame, CA, USA). TUNEL-positive
cells were detected by 3,3′-diaminobenzidine tetrahydrochloride-nickel (Vector
Laboratories). TNF-α-positive cells were identified by immunohistochemistry using an
antibody specific for TNF-α (Santa Cruz Biothechnology, Santa Cruz, CA, USA). There was
no immunostaining with matched control IgG (data not shown). To analyse proliferating
fibroblasts, specimens were double-immunostained for HSP47 and proliferating cell nuclear
antigen (PCNA) (Santa Cruz Biotechnology) with secondary detection by avidin–biotin–
peroxidase complex and avidin–biotin–alkaline phosphatase complex (Vector Laboratories).
Chromogens 3,3′-diaminobenzidine and Vector Red were from Vector Laboratories. Cell
counts were made at ×1,000 magnification. All counting and measurements were done under
blinded conditions by one examiner and confirmed by a second independent examiner, with
both examiners calibrated by a trained pathologist.
Confocal laser scanning microscopy
FOXO1 nuclear translocation of fibroblasts was detected by three-colour confocal laser
scanning microscopy with antibodies specific for FOXO1 and HSP47 combined with
nuclear staining with 7-aminoactinomycin D (7-AAD; Molecular Probes, Eugene, OR,
USA). FOXO1 antibody was detected by biotinylated secondary antibody followed by
Alexa Fluor 488-conjugated streptavidin (Molecular Probes) and HSP47 antibody was
detected by Alexa Fluor 514-conjugated secondary antibody (Molecular Probes). For better
colour contrast, HSP47 staining was displayed by a blue colour using Carl Zeiss LSM image
software. Immunofluorescence images were captured by confocal laser scanning microscopy
(Axiovert-100M; Carl Zeiss; Thornwood, NY, USA) of healing connective tissue.
Fibroblasts with FOXO1 in the nuclear compartment were counted by comparing individual
images with merged images (see Electronic supplementary material [ESM] Fig. 1). For each
antibody, a matched control antibody was used as a negative control and no immunostaining
was detected (data not shown).
Biochemical analysis of wounded tissue
Tissue at the wounded site was harvested using a 2.0 mm punch biopsy and frozen in liquid
nitrogen. Specimens from a group were combined, placed in cytoplasmic lysis buffer
containing protease inhibitors (Pierce, Rockford, IL, USA) and disrupted using Fast Prep
(Q-Biogene, Solon, OH, USA). The nuclei were separated from cytoplasmic proteins by
centrifugation. Protein in each lysate was determined using a BCA protein assay kit (Pierce).
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TNF-α levels were quantified using an ELISA kit (R&D Systems, Minneapolis, MN, USA).
Caspase-3/7 activity was measured by a luminometric kit (Promega, Madison, WI, USA).
FOXO1 activation was measured in nuclear protein extracts obtained by lysis of the nuclear
pellet. DNA binding activity was measured by ELISA (Active Motif, Carlsbad, CA, USA).
To quantify the mRNA levels, total RNA was extracted using an RNeasy total RNA
isolation kit (Qiagen, Valencia, CA, USA) and a QIAshredder spin column (Qiagen). cDNA
was prepared using a reverse transcription kit (Applied Biosystems, Foster City, CA, USA).
TaqMan primer and probe sets for murine Tnf-α (also known as Tnfa) and caspase-3
(Casp-3) were purchased from Applied Biosystems. Results were normalised with respect to
an 18S ribosomal primer and probe set purchased from Applied Biosystems. Each value is
the mean of three independent assays ± SEM. One-way ANOVA was used to determine
significance between groups at the p<0.05 level.
mRNA profiling and FOXO1 siRNA
Primary human adult dermal fibroblasts were purchased from Cambrex (Walkers-ville, MD,
USA) and cultured in Dulbecco’s modified Eagle’s medium (Cambrex) supplemented with
10% (vol./vol.) FBS. All assays were performed under serum-free conditions. Fibroblasts
were transfected with silencing FOXO1 small interfering RNA (siRNA)
(r[GCCCUGGCUCUCACAGCAA]d[TT]) or non-silencing siRNA
(r[GATGGCCTCTACTTTACCC]dTT) for 48 h followed by TNF-α (20 ng/ml) or alone for
6 h as described previously [42]. Some cells were incubated serum-free for 24 h and then
stimulated with TNF-α (20 ng/ml) for 6 h. Total RNA was isolated using an RNeasy kit
(Qiagen, Valencia, CA, USA). mRNA profiling was performed using a GeneChip Human
Genome U133 Plus 2.0 microarray (Affymetrix, Santa Clara, CA, USA). Reverse
transcription and real-time quantitative PCR (qPCR) of selected genes was performed to
validate microarray result using Taqman reverse transcription reagents and primers and
probe sets (Applied Biosystems). Results were normalised with respect to the value obtained
for the housekeeping gene, RPL32, a ribosomal protein. GSEA was performed using GSEA
software (www.broadinstitute.org/gsea, accessed 26 August 2009) as described previously
[43]. GSEA determines whether an a priori defined set of genes shows statistically
significant differences between two groups. GSEA was performed using gene sets
downloaded from the GSEA websites. No data collapsing or filtering was performed.
Statistical analysis
For histological sections, eight to 12 fields were typically examined per section. One-way
ANOVA was used to determine significance between groups. For real-time qPCR Student’s
t test was used to determine significance between groups. Significance was set at the p<0.05
level.
Results
A small excisional wound was placed in the scalp of normoglycaemic and diabetic db/db
mice. On day 4, a time point at which there was little wound closure in either diabetic or
normoglycaemic groups, the diabetic group revealed threefold higher mRNA and protein
levels of TNF-α compared with the normoglycaemic mice (p<0.05; Fig. 1a, b). We next
examined the caspase-3 activity, apoptosis and FOXO1 DNA binding activity in healing
wounds. The level of caspase-3/7 activity in healing wound tissue was almost fourfold
higher in diabetic mice than in normoglycaemic mice during wound healing (Fig. 1c). When
fibroblast apoptosis was measured there was a 2.5-fold higher level in the diabetic group
compared with the normoglycaemic mice (Fig. 1d). Since TNF-α induces fibroblast pro-
apoptotic activity through induction of the transcription factor FOXO1 [42], we measured
FOXO1 DNA binding activity in healing tissue. Diabetes increased FOXO1 DNA binding
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activity twofold compared with wounds in normoglycaemic animals (Fig. 1e). Thus, diabetic
healing in vivo is characterised by a number of variables that have been shown to be
stimulated by TNF-α in vitro, including diabetes-enhanced fibroblast apoptosis, caspase-3/7
activity and FOXO1 activation.
To examine the role of TNF-α in impaired healing, mice were treated with the specific
inhibitor pegsunercept or vehicle alone. On day 5, the gap between the edges of the healing
connective tissue and healing epithelium was approximately 1.7-fold larger in the diabetic
mice (Fig. 2a, c and ESM Fig. 2a, b). In the normoglycaemic mice, new connective tissue
filled approximately 50% of the original wound site (Fig. 2e), whereas it was approximately
25% filled in the diabetic animals. For both normoglycaemic and diabetic groups, treatment
with TNF-α inhibitor had no effect on healing on day 5. From day 5 to day 9 after wounding
there was relatively little improvement in the diabetic wounds, while the normoglycaemic
animals had healed extensively (Fig. 2 and ESM Fig. 2). Treatment with pegsunercept had a
significant effect on diabetic healing at this time point. Vehicle-treated diabetic mice had
gaps between epithelial and connective tissue edges of the wounds that were approximately
70% larger than in the pegsunercept-treated diabetic mice (Fig. 2b, d; p<0.05). Pegsunercept
also increased the percentage of the wound filled with new connective tissue by
approximately 50% in the diabetic mice and had no effect on normoglycaemic healing (Fig.
2f; p<0.05).
Experiments were performed to assess the level of fibroblast apoptosis with and without
TNF-α inhibitor. Day 9 was examined in db/db mice since pegsunercept had a significant
impact on healing at this time point. The percentage of apoptotic fibroblasts in diabetic
healing wounds was fivefold higher compared with the normoglycaemic group (Fig. 3a and
ESM Fig. 3). After inhibition of TNF-α, fibroblast apoptosis was reduced by >50% in both
the diabetic and non-diabetic mice, although the absolute decrease in the diabetic mice was
much greater (p<0.05; Fig. 3a). The number of fibroblasts per mm2 was almost twofold
higher in the normoglycaemic compared with the diabetic (Fig. 3c, ESM Fig. 4; p<0.05).
Fibroblast density in diabetic mice treated with TNF-α inhibitor increased by 78% compared
with vehicle-treated mice (p<0.05).
The impact of diabetes on fibroblast apoptosis and density was also measured in
streptozotocin-induced diabetic mice. The percentage of apoptotic fibroblasts was increased
fourfold in the streptozotocin diabetic compared with the matched normoglycaemic mice
(Fig. 3b). Treatment with pegsunercept blocked the increase in these mice caused by
diabetes. The number of fibroblasts per mm2 was almost 50% higher in the normal
compared with the streptozotocin-induced diabetic animals (Fig. 3d). Treatment with the
pegsunercept increased fibroblast density by 71% compared with streptozotocin-induced
diabetic mice treated with vehicle alone. The increase in cell density is consistent with the
large change in absolute number of apoptotic fibroblasts in the diabetic animals of both
models.
The impact of diabetes and inhibition of TNF-α on proliferation of fibroblasts was measured
(Fig. 3e). The number of proliferative fibroblasts was fourfold higher in the normoglycaemic
than diabetic mice. Treatment with pegsunercept in diabetic mice significantly increased the
number of proliferating fibroblasts. However, pegsunercept had no effect on fibroblast
proliferation in normoglycaemic mice, indicating that the high levels of TNF-α in the
diabetic mice were problematic whereas they were not in the normoglycaemic group.
In order to explore the effect of diabetes and TNF-α inhibition on inflammation, PMNs were
counted in both diabetic and normoglycaemic groups of the two animal models. In the
normoglycaemic and diabetic db/db groups the inflammatory infiltrate was relatively large
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on day 5 (Fig. 4a and ESM Fig. 5). However, it was significantly less on day 9 in the
normoglycaemic group but remained high at this time point in the diabetic mice. When
diabetic mice were treated with pegsunercept there was a significant reduction in
inflammatory infiltrate on days 5 and 9, while there was an improvement in the
normoglycaemic group only on day 5 (p<0.05; Fig. 4a). The inflammatory infiltrate was also
assayed in the streptozotocin model (Fig. 4b). The PMN infiltrate was significantly higher in
the diabetic group than control group (p<0.05) and TNF-α inhibition reduced the PMN
infiltrate in the diabetic group (p<0.05), consistent with its anti-inflammatory activity.
In vitro, TNF-α stimulates FOXO1 DNA binding activity in fibroblasts [42]. We assessed
the number of cells that produced TNF-α and determined whether it was affected by
treatment with pegsunercept (Fig. 4c). The number of TNF-α-positive cells was 3.5-fold
higher in the diabetic group than the normoglycaemic and treatment with pegsunercept
reduced the number of TNF-α-producing cells by 60%, both of which were significant.
When FOXO1 is activated it translocates to the nucleus and exhibits increased DNA binding
activity. Upon deactivation it is translocated out of the nucleus. To assess FOXO1 activation
in vivo we examined the level of FOXO1 nuclear translocation in fibroblastic cells by three-
colour confocal laser scanning microscopy (Fig. 4d). FOXO1 nuclear translocation in
fibroblasts in type 2 diabetic mice was increased threefold compared with the
normoglycaemic mice on day 5. Blocking TNF-α inhibited almost all of the increase caused
by diabetes, suggesting that TNF-α played a significant role in increased FOXO1 activation
in fibroblasts in diabetic wound healing.
We have previously shown that TNF-α induces fibroblast apoptosis through induction of the
transcription factor, FOXO1 [42]. To better understand the impact of TNF-α on fibroblasts
and the role that FOXO1 might play, GSEA was performed. We compared TNF-α-
stimulated vs unstimulated fibroblasts as well as fibroblasts transfected with FOXO1 siRNA
compared with scrambled siRNA prior to TNF-α stimulation. A false discovery rate was set
at <5%. Compared with non-stimulated cells, TNF-α significantly increased mRNA levels
of genes involved in apoptosis by increasing apoptosis, Akt and p53 gene sets but not
mitochondrial or cell-cycle gene sets (Table 1). FOXO1 siRNA decreased gene expression
in apoptosis, Akt, mitochondrial and cell-cycle gene sets but not p53. Individual genes
identified by the GSEA software for the ‘apoptosis’ pathway are listed in Table 2. Several
were upregulated by TNF-α more than 1.7-fold and their upregulation was blocked by
FOXO1 siRNA (0.58 or less), demonstrating the functional role of FOXO1 in their
regulation. These included TNF-α (also known as TNF), TNF superfamily member 10
(TNFSF10), baculoviral IAP repeat-containing 2 (BIRC2 ), BIRC3, interferon regulatory
factor-1 (IRF1), IRF2, IRF7, v-rel reticuloendotheliosis viral oncogene homologue A
(RELA), nuclear factor of kappa light polypeptide gene enhancer in B cells-1 (NFKB1),
nuclear factor κB (NFKB) inhibitor (NFKBI), NFKBI-alpha (NFKBIA), NFKBI-beta
(NFKBIB), NFKBI-epsilon (NFKBIE), TNF receptor-associated factor 1 (TRAF1), CASP1,
CASP7, CASP10, TNF receptor super-family member 6 (FAS), TNF receptor superfamily
member 1B (TNFRSF1B), TNFRSF10B, BCL2-like 11 (BCL2L11), BH3 interacting domain
death agonist (BID) and Jun oncogene (JUN). Genes included in the other apoptotic
pathways and their stimulation by TNF-α and effect of FOXO1 siRNA are shown in ESM
Tables 1, 2, 3 and 4.
Because TNF-α also induces inflammation, inflammatory pathways were examined
including pathways designated by the GSEA software as ‘inflammation’, ‘cytokines’, ‘Toll’
and ‘NFKB’. GSEA indicated that that each of these gene sets had mRNA levels enhanced
by TNF-α (Table 1). Unexpectedly, FOXO1 silencing significantly reduced mRNA levels
for all four of these gene sets. Mediators included in the ‘inflammation’ gene set that were
upregulated by TNF-α stimulation and blocked by FOXO1 silencing included TNF-α,
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interleukin-1 alpha (IL1α), interleukin-6 (IL6), IL8, IL15, colony-stimulating factor 1
(CSF1), CSF2 and CSF3 (Table 3). Genes included in the other inflammatory pathways and
their stimulation by TNF-α and effect of FOXO1 siRNA are shown in ESM Tables 5, 6 and
7.
To validate microarray results, real-time qPCR was carried out for selected genes. When
microarray results were directly compared with real-time qPCR results TNF-α was shown to
stimulate a more than 1.7-fold increase in IL1α, IL6, IL8, TNF-α and FAS in both types of
assays (Fig. 5a). Similarly, when cells were first transfected with FOXO1 siRNA or
scrambled siRNA both microarray and real-time qPCR results indicated that FOXO1 siRNA
caused a 1.7-fold or more decrease in the mRNA values for each gene tested (Fig. 5b).
Discussion
Multiple factors contribute to impaired wound healing. Results presented here indicate that
TNF-α is elevated in both type 1 and type 2 diabetic wounds. When TNF-α is specifically
inhibited, healing of both type 1 and type 2 diabetic wounds is improved, including the rate
of epithelial coverage and formation of new connective tissue. TNF-α inhibition
significantly enhanced fibroblast density. To investigate mechanisms, we further examined
fibroblast proliferation and apoptosis. The effect of diabetes on fibroblast proliferation and
apoptosis was reversed by blockage of TNF-α. To further investigate how TNF-α affects
fibroblast apoptosis in diabetic wound healing we examined the pro-apoptotic transcription
factor FOXO1. Wounds in type 2 diabetic mice had increased FOXO1 DNA binding activity
and increased FOXO1 nuclear translocation in fibroblasts in vivo. Moreover, this increase
was driven by TNF-α, since nuclear translocation was significantly reduced by TNF-α
inhibition. In contrast, inhibiting TNF-α had relatively little effect on the normoglycaemic
mice, suggesting that normal levels of TNF-α are not problematic. Increased FOXO1
activity may also be implicated in type 1 diabetic mice, since elevated TNF-α was observed
in type 1 diabetic mice.
Apoptosis is rapid, and at the end-stage of apoptosis the cell breaks down into small
apoptotic bodies that are rapidly removed and are not retained in the tissue. We counted only
identifiable cells undergoing apoptosis, which exist transiently during a window of ~2 h. A
rate of 2.5% apoptotic fibroblasts in a 2 h time frame would translate to 30% over a 24 h
period, indicating that the level observed could have a physiological impact. Since the level
of fibroblast apoptosis was significantly higher in diabetic wounds, the cumulative effect
would be greater in diabetic mice.
It is well known that diabetes causes prolonged inflammation during wound healing [1, 4,
6]. One mechanism through which diabetes may cause enhanced inflammation during the
healing process is through the activity of AGEs or elevated levels of TNF-α [25]. The latter
is supported by a recent report that blocking TNF-α with an antibody improves healing,
which was associated with a decrease in inflammation [44]. It has also been reported that
mice with genetic ablation of TNF-R1 have accelerated wound healing with reduced
leucocyte infiltration [45]. Persistently high levels of TNF-α from systemic or local
application in vivo interfere with dermal wound healing [26, 46, 47], which is consistent
with the effects seen in diabetic wound healing where TNF-α is elevated.
To explore pathways that may be regulated by TNF-α and to determine whether they were
mediated by FOXO1 in fibroblasts, siRNA studies were carried out in conjunction with
mRNA profiling and GSEA. GSEA examines an entire ‘gene set’ and can distinguish
differences between groups that might be missed if each gene were examined separately,
since individual genes may exhibit changes that do not meet a pre-conceived threshold, or
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there may be a confusing pattern of inconsistent changes [43, 48]. This analysis indicated, as
expected, that mRNA levels of an ‘apoptosis’ gene set were higher in TNF-α-stimulated
cells. TNF-α also increased mRNA levels of Akt and p53 apoptotic genes. Diabetic wound
healing was associated with increased nuclear translocation in fibroblasts that was reversed
by the inhibition of TNF-α. To determine whether FOXO1 mediated the TNF-α-induced
apoptotic pathway, RNAi studies were carried out in conjunction with GSEA. FOXO1
siRNA blocked TNF-α induced upregulation of apoptosis pathway and Akt pathway gene
sets, but had no effect on the p53 pathway gene set. Interestingly, FOXO1 siRNA decreased
levels of the mitochondrial apoptotic and cell-cycle gene sets even though they were not
modulated by TNF-α. The former is consistent with a report that FOXO1 plays an important
role in apoptosis related to DNA damage that involves the activity of genes that regulate the
cell cycle [49]. Surprisingly, FOXO1 siRNA also blocked each of the pro-inflammatory
gene sets induced by TNF-α, indicating a previously unrecognised function of FOXO1 in
mediating TNF-α-induced inflammatory gene expression.
In summary, diabetes affects wound healing by significantly increasing fibroblast apoptosis
and decreasing fibroblast proliferation while decreasing fibroblast density. Each of these
effects is reversed by TNF-α inhibition. The improved healing from decreased fibroblast
apoptosis is consistent with a previous report that treatment with a caspase inhibitor that
blocks apoptosis increases fibroblast density and improves the repair of connective tissue
following a bacteria-induced wound [50]. In vitro results indicate that TNF-α enhances
inflammatory and pro-apoptotic gene expression in fibroblasts through the transcription
factor FOXO1. This may be important and is supported by findings that FOXO1 is elevated
during healing of wounds in diabetes.
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Fig. 1.
Diabetes increases TNF-α mRNA and protein levels, fibroblast apoptosis, caspase-3/7
activity and FOXO1 DNA binding in healing wounds. A 1.5 mm excisional full thickness
wound was created in the scalp of db/db diabetic (black bars) and normoglycaemic mice
(white bars). a Total RNA was isolated and TNF-α mRNA levels were measured by real-
time PCR. b TNF-α protein levels were measured in protein extracts of healing wounds by
ELISA and are representative of two experiments. c Caspase activity was measured in
cytoplasmic extracts with a luminometric kit. d, e The wounded tissue was recovered with a
2.0 mm dermal microtome and cytoplasmic and nuclear proteins were extracted. d
Apoptotic fibroblasts were measured by the TUNEL assay 4 days after wounding (n=6 per
group). Prior to wounding there was little to no apoptosis detected (data not shown). e
FOXO1 activity was measured in extracted nuclear proteins obtained 4 days after wounding
using a transcription factor activation ELISA. For a, c and e each value is the mean±SEM of
three separate experiments. *Significant difference between normoglycaemic and diabetic
mice (p<0.05)
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Fig. 2.
Healing of excisional wounds is impaired in db/db mice and improved by inhibition of TNF-
α. A 1.5 mm excisional wound was placed in the scalp of db/db mice and their non-diabetic
littermates. Mice were treated by i.p. injection of pegsunercept (5 mg/kg) or vehicle alone
starting 2 days after wounding and killed 5 days (a, c, e) or 9 days (b, d, f) after wounding.
The gap between the epithelium (a, b), connective tissue (c, d) and the per cent fill of the
wound site by connective tissue (e, f) was assessed by image analysis of haematoxylin and
eosin-stained sections at the centre of each lesion. Each value is the mean ± SE of n=6–7
mice. *p<0.05 between pegsunercept- and vehicle-treated groups. White bars, vehicle-
injected normoglycaemic mice; diagonal hatched bars, pegsunercept-injected
normoglycaemic mice; black bars, vehicle-injected db/db diabetic mice; horizontal hatched
bars, pegsunercept-injected db/db mice
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Fig. 3.
TNF-α inhibition reduces fibroblast apoptosis and increases fibroblast numbers in diabetic
mice. Excisional wounds were created in the scalp of db/db (a, c, e) and streptozotocin-
induced diabetic mice (b, d) or their matched normoglycaemic controls. Mice were treated
with pegsunercept or vehicle alone starting on day 2 as described in Fig. 2 and killed 9 days
after wounding (a, c) or 5 days after wounding (b, d, e). The number of fibroblasts per mm2
was assessed by immunohistochemistry using an antibody specific for HSP47, a fibroblast
marker (c, d). There was no immunostaining with matched control IgG (data not shown).
Apoptotic fibroblasts were measured by double staining as TUNEL-positive and HSP47-
positive (a, b). Proliferative fibroblasts were identified as both HSP47- and PCNA-positive
by immunohistochemistry (e). Each value is the mean ± SEM for n=5–7 mice per group.
*p<0.05 between pegsunercept- and vehicle-treated groups. a, c, e White bars, diagonal
hatched bars, black bars and horizontal hatched bars indicate vehicle-injected
normoglycaemic mice, pegsunercept-injected normoglycaemic mice, vehicle-injected db/db
diabetic mice and pegsunercept-injected db/db mice, respectively. b, d White bars, black
bars and horizontal hatched bars indicate normoglycaemic mice, streptzotocin-induced type
1 diabetic mice with vehicle injection, and pegsunercept-injected streptzotocin-induced
diabetic mice, respectively
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Fig. 4.
TNF-α inhibition decreases infiltration of inflammatory cells and FOXO1 activation.
Excisional wounds were created in db/db (a, d) or streptozotocin-induced diabetic mice (b,
c) or their matched normoglycaemic controls and treated with pegsunercept or vehicle alone
starting on day 2. The number of PMNs was counted in haematoxylin and eosin-stained
sections (a, b). TNF-α-immunopositive fibroblasts were identified by double immunohisto-
chemistry using an antibody specific for TNF-α simultaneously with an antibody specific for
HSP47 (c)(n=5 per group). FOXO1 nuclear translocation in fibroblasts was assessed in
three-colour confocal laser scanning microscopy with antibodies specific for FOXO1 or
HSP47. Nuclei were identified by fluorescent nuclear stain, 7-AAD. There was no
immunostaining with matched control IgG (data not shown). Each value is the mean±SEM
of n=5–7 mice. *p < 0.05 between pegsunercept- and vehicle-treated groups. a, d White
bars, diagonal hatched bars, black bars and horizontal hatched bars indicate vehicle-injected
normoglycaemic mice, pegsunercept-injected normoglycaemic mice, vehicle-injected db/db
diabetic mice and pegsunercept-injected db/db mice, respectively. b, c White bars, black
bars, and horizontal hatched bars indicate normoglycaemic mice, streptzotocin-induced type
1 diabetic mice with vehicle injection and pegsunercept-injected streptzotocin-induced
diabetic mice, respectively
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Fig. 5.
FOXO1 RNAi inhibits TNF-α upregulation of pro-inflammatory and pro-apoptotic genes in
human fibroblasts. Real-time qPCR (white bars) was performed on total RNA isolated from
human fibroblasts that had been stimulated with TNF-α (20 ng/ml) for 6 h. In some groups,
cells were transfected with FOXO1 or scrambled siRNA and then stimulated with TNF-α. a
mRNA levels for TNF-α compared with unstimulated cells. b mRNA levels for FOXO1
siRNA plus TNF-α compared with scrambled siRNA plus TNF-α. For real-time qPCR the
experiment was conducted three times with similar results. A representative experiment is
shown. The corresponding mean values obtained by microarray (black bars) analysis (see
Tables 2 and 3) are presented. The horizontal bar represents a 1.7-fold increase (a) or a 1.7-
fold decrease (b) in mRNA levels. Note that vertical axes are on logarithmic scales
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Table 2
Apoptotic genes induced by TNF-α and inhibited by FOXO1 siRNA
Gene TNF-α FOXO1 siRNA
Median Mean Median Mean
TNFSF10 a 20.03 14.26 0.04 0.04
BIRC3 a 17.73 18.69 0.03 0.40
IRF7 a 12.94 9.67 0.11 0.27
NFKB1E a 7.06 10.90 0.05 0.25
TRAF1 a 6.97 28.05 0.04 0.25
CASP1 a 4.34 3.07 0.25 0.28
NFKB1A a 4.31 6.14 0.10 0.28
IRF1 a 3.98 13.66 0.04 0.30
NFKB1 a 3.27 4.19 0.16 0.35
NFKB1B a 3.20 3.23 0.28 0.48
FAS a 2.80 2.94 0.18 0.19
BCL2L11 a 2.78 2.10 0.47 0.53
RELA a 2.56 2.36 0.32 0.25
CASP7 a 2.51 1.99 0.44 0.43
BID 2.48 2.28 0.50 0.39
CASP10 a 2.44 2.48 0.40 0.46
TNFRSF1B a 2.32 2.20 0.52 0.58
TNF-α a 2.18 7.84 0.02 0.30
IRF2 a 2.14 2.09 0.52 0.42
MYC 2.07 1.90 0.55 0.73
TNFRSF10B a 2.04 2.06 0.43 0.43
BIRC2 a 1.99 2.22 0.37 0.48
CASP3 1.95 1.66 0.67 0.68
JUN a 1.93 4.63 0.11 0.08
TRADD 1.80 1.47 0.59 0.52
CASP4 1.77 1.46 0.66 0.54
CYCSs 1.63 1.63 0.44 0.53
TNFRSF1A 1.58 1.37 0.81 0.68
CASP9 1.56 1.28 0.96 0.82
BCL2L11 1.50 1.52 0.26 0.33
IKBKB 1.43 1.28 0.25 0.37
RIPK1 1.42 1.34 0.41 0.51
MDM2 1.41 1.32 0.41 0.33
TRAF2 1.39 1.44 0.60 0.47
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Gene TNF-α FOXO1 siRNA
Median Mean Median Mean
BIRC4
 (also known
 as XIAP)
1.36 1.36 0.52 0.40
IRF5 1.33 1.24 0.76 0.75
FASL 1.31 1.09 0.69 0.62
TRAF3 1.30 1.40 0.43 0.69
IRF3 1.30 1.42 0.63 0.65
IKBKG 1.30 1.31 0.80 0.72
PRF1 1.26 1.19 0.79 0.69
CHUK 1.25 1.19 0.81 0.78
CASP2 1.19 1.26 0.46 0.64
LTA 1.19 2.95 1.06 0.77
MAPK10 1.15 1.46 0.59 0.66
BAD 1.13 1.30 0.52 0.64
BCL2 1.08 2.70 0.31 0.42
BIRC5 1.07 1.09 0.46 0.51
BNIP3L 1.04 0.85 1.52 1.95
MAP2K4 1.02 0.99 0.70 0.82
DFFA 1.02 0.91 0.96 1.13
IRF6 1.00 1.34 0.59 0.59
TNFRSF25 0.99 1.05 0.42 0.71
APAF1 0.99 1.01 0.67 0.71
FADD 0.98 0.84 0.99 1.11
CASP6 0.97 0.79 0.77 1.41
TP53 0.95 1.01 0.58 0.87
CASP8 0.94 1.08 0.15 0.50
TP73 0.94 1.11 0.30 0.74
HELLS 0.93 0.97 0.39 0.32
GZMB 0.93 0.96 0.92 0.78
BAX 0.85 0.83 0.69 0.71
HRK 0.83 0.94 0.39 0.98
TNFRSF21 0.79 0.69 0.47 0.58
IRF4 0.74 1.12 1.05 0.92
MAP3K1 0.72 1.06 0.65 0.47
Human primary fibroblasts were treated as described in the Methods. mRNA profiling was carried out. The mean and median values for TNF-α vs
unstimulated and FOXO1 siRNA plus TNF-α vs scrambled siRNA plus TNF-α are shown for triplicate experiments. Genes defined in the apoptosis
pathway gene set (www.broadinstitute.org/gsea) are shown
a
Both a 1.7-fold or more stimulation by TNF-α and a 1.7-fold decrease (0.58, which is the fold decrease equivalent to 1.7 fold stimulation) by
FOXO1 siRNA for both mean and median values
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Table 3
Inflammatory genes induced by TNF-α and inhibited by FOXO1 siRNA
Gene TNF-α FOXO1 siRNA
Median Mean Median Mean
IL8 298.69 294.75 0.01 0.26
IL11 86.27 57.7 0.58 0.76
IL6 a 14.52 13.53 0.04 0.39
IL1-α a 10.83 66.63 0.01 0.17
CSF2 a 6.24 6.95 0.15 0.30
IL15 a 3.60 3.32 0.16 0.20
TNF-α a 2.18 7.84 0.02 0.30
IL4 2.18 2.07 1.23 0.90
CSF1 a 2.16 2.31 0.07 0.19
IL12a 2.07 1.56 0.36 0.35
CSF3 a 1.91 2.11 0.10 0.08
IFNB1 1.54 1.57 0.02 0.04
TGFB2 1.47 1.53 0.14 0.11
IL10 1.31 1.31 1.00 0.86
PDGF-α 1.27 1.26 0.17 0.18
IL2 1.24 1.60 1.02 0.90
TGFB3 1.23 1.08 0.79 0.78
LT-α (also known as LTA) 1.19 2.95 1.06 0.77
IL7 1.17 1.04 0.21 0.20
IL13 1.11 1.01 0.68 0.74
IFNA1 1.08 1.15 0.83 0.83
TGFB1 1.06 1.19 0.82 0.79
IL3 1.04 1.14 0.48 1.06
CD4 0.94 6.79 0.73 0.64
IFNG 0.82 0.97 0.94 0.87
IL5 0.80 0.86 0.90 0.84
IL12B 0.74 0.80 1.23 0.98
HLA-DRA 0.47 2.00 0.38 2.72
HLA-DRB1 0.12 2.06 0.63 2.64
Human primary fibroblasts were treated as described in the Methods. mRNA profiling was carried out. The mean and median values for TNF-α vs
unstimulated and FOXO1 siRNA plus TNF-α vs scrambled siRNA plus TNF-α are shown for triplicate experiments. Genes defined in the
inflammation pathway gene set (www.broadinstitute.org/gsea) are shown
a
Both a 1.7-fold or more stimulation by TNF-α and a 1.7-fold decrease (0.58, which is the fold decrease equivalent to 1.7 fold stimulation) by
FOXO1 siRNA for both mean and median values
Diabetologia. Author manuscript; available in PMC 2011 July 6.
